Want to invest in pharma & capex themes? These are the stocks to consider
“In the next one or two quarters, positive news flow on the pharma side, especially from the US, will start. Channel checks suggest that the pressure on pricing is reducing a lot. Most of the unviable smaller players are out of business. The market has consolidated into a few companies and people are identifying molecules which can have competitive edge,” says Daljeet Singh Kohli.
